A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine when administered with and without diphtheria, tetanus, acellular pertussis and inactivated polio (DTaP-IPV) vaccine and varicella vaccine to healthy children four to six years of age - MMR-158

GlaxoSmithKline Biologicals0 个研究点目标入组 4,000 人开始时间: 2015年6月11日最近更新: 2015年7月10日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: GlaxoSmithKline Biologicals
入组人数: 4,000

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Subjects who the investigator believes that they and/or their parent(s) or LAR/s can and will comply with the requirements of the protocol
•Male or female subjects 4 to 6 years of age at the time of vaccination
•Written informed consent is obtained from the parent(s)/LAR(s) of the subject (assent will be obtained from subjects in line with local rules and regulations)
•Subjects in stable health as determined by investigator’s physical examination and assessment of subjects’ medical history
•Subjects received either a single dose of M-M-R II, M-M-R VaxPro or ProQuad in the second year of life
•For subjects enrolled in the sub-cohort receiving co-administered DTaP-IPV and VV:
•-subjects received previous DTaP vaccine doses with INFANRIX® and/or PEDIARIX® for the first three doses and INFANRIX® for the fourth dose of the DTaP-containing vaccine.
•-subjects received a first dose of VV in the second year of life
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 4000
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Child in care
•Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before the day of study vaccination/s or planned during the entire study period
•Previous vaccination with a second dose of measles, mumps, rubella containing vaccine/s
•Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting 180 days prior to Day 0 or any planned administration of immunosuppressive and immune-modifying drugs during the entire study. Inhaled and topical steroids are allowed.
•Administration of immunoglobulins and/or any blood products during the period starting 180 days before entering the study or planned administration from the date of vaccination through the immunogenicity evaluation at Visit 2
•Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting 30 days prior to the study vaccination/s and ending 42 days after the vaccination/s (at Visit 2), with the exception of live intranasal or inactivated influenza (flu) vaccine, which may be given at any time, including the day of study vaccination/s. Inactivated influenza vaccine must be administered at a different location from the study vaccine. Any age appropriate vaccine may be given starting at Visit 2, and anytime thereafter.
•Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
•History of measles, mumps, and/or rubella disease
•Known exposure to measles, mumps and/or rubella during the period starting 30 days prior to enrollment
•Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
•History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including systemic hypersensitivity to neomycin or gelatin
•Blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems
•Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Fever is defined as temperature =38°C (100.4°F) measured by any age appropriate route. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection without fever
•Active untreated tuberculosis according to the subject’s medical history
•Any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.
•In addition, for subjects enrolled in the sub-cohort receiving co-administered DTaP-IPV+VV:
•Previous vaccination with a second dose of varicella-containing vaccine
•Receipt of any varicella-containing vaccine during the period starting 90 days before the day of study vaccination
•History of varicella/zoster disease
•Known exposure to varicella/zoster during the period starting 30 days prior to enrollment
•History of diphtheria, tetanus, pertussis, and/or poliomyelitis disease
•Vaccination against diphtheria, tetanus, pertussis or polio given after the second year of life
•Occurrence of transient thrombocytopenia or neurological complications following an earlier immunization against diphtheria and/or tetanus toxoids
•Following a previous administration of DTP vaccine: temperature >= 40.6°C

研究者

发起方

GlaxoSmithKline Biologicals

相似试验

进行中（未招募）

不适用

EUCTR2011-003672-36-EEGlaxoSmithKline Biologicals1,000

进行中（未招募）

不适用

Immunogenicity and safety study of GSK Biologicals´ combined measles-mumps-rubella vaccine in subjects seven years of age and older (209762).

EUCTR2011-003672-36-SKGlaxoSmithKline Biologicals S.A.1,000

进行中（未招募）

不适用

A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A as compared to the Dresden-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A. - FLU D-PAN H1N1-017Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 to 60 years.

EUCTR2009-014419-11-DEGlaxoSmithKline Biologicals320

进行中（未招募）

1 期

EUCTR2009-014419-11-FRGlaxoSmithKline Biologicals320

进行中（未招募）

不适用

A phase IIIB, partially blind, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children during the second year of life following a 4-week and a 12-month interval between two doses - MMRV-042 & MMRV-045Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.

EUCTR2004-004371-11-DEGlaxoSmithKline Biologicals540